30.25
+0.23(+0.77%)
Currency In USD
| Previous Close | 30.02 |
| Open | 29.77 |
| Day High | 30.42 |
| Day Low | 29.52 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Volume | 437,736 |
| Average Volume | 742,698 |
| Market Cap | 1.97B |
| PE | -9.73 |
| EPS | -3.11 |
| Moving Average 50 Days | 29.97 |
| Moving Average 200 Days | 40.09 |
| Change | 0.23 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $909.5 as of May 16, 2025 at a share price of $30.25. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $1,823.39 as of May 16, 2025 at a share price of $30.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
GlobeNewswire Inc.
May 09, 2025 11:01 AM GMT
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master r
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
GlobeNewswire Inc.
Apr 24, 2025 11:00 AM GMT
Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced th